白云山(00874)发布公告，于2025年9月26日，买方(广药二期基金，公司控制的合伙企业)与卖方 (AHAPL)订立了股份转让合同。根据股份转让合同，买方同意收购，卖方同意出售目标公司(南京医药 （600713）股份有限公司)11.04%股权，收购对价为人民币7.488亿元。于收购事项完成后，买方将持有 目标公司11.04%股权。 同时，为加强公司与目标公司的战略合作，公司、买方及目标公司同步订立了战略投资协议。合作内 容： (i)资本层面合作 公司支持广药二期基金拟通过协议方式受让AHAPL所持目标公司股票方式战略投资目标公司，并持有 目标公司1.45亿股股票，即目标公司11.04%股权。 战略投资协议订约方将根据业务合作和资本运作需求，在遵守相关法律法规的前提下，在合适时机通过 包括但不限于成立合资公司、战略投资、股权投资基金等开展合作。 (ii)自有工业品种分销管道合作 公司和目标公司积极制定市场拓展与管道共用方案，整合优化供应链资源和物流配送网路，建立稳定、 高效的供应链体系;针对自有工业品种，通过有效机制开展市场准入和管道销售，相互提升产业链合作 等级，聚焦主营业务效益，增强公司和目标公司双方上 ...

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. announced the acquisition of 11.04% shares of Nanjing Pharmaceutical Co., Ltd. from Alliance Healthcare Asia Pacific Limited for 749 million RMB, making Baiyunshan the second-largest shareholder of Nanjing Pharmaceutical [1][2] Group 1 - The acquisition price is based on the average closing price of Nanjing Pharmaceutical's shares over the previous 60 trading days, set at 5.18 RMB per share [1] - The strategic investment agreement signed includes collaboration in capital cooperation, distribution channels for proprietary industrial products, and cooperation in traditional Chinese medicine [1][2] Group 2 - This transaction is expected to enhance Baiyunshan's business cooperation with Nanjing Pharmaceutical, optimize regional industrial layout, and strengthen competitive advantages in the pharmaceutical distribution business [2] - The Baiyunshan-funded Guangzhou Traditional Chinese Medicine Phase II Fund was established with a total investment of 1.499 billion RMB, focusing on investments in the biopharmaceutical and health sectors [2]